(Q43777913)

English

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial

scientific article published on 18 August 2003

Statements

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial (English)
Thomas G Filloon
Scott Rollins
Jose C Nicolau
COMMA Investigators
18 August 2003
1184-1190

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit